Lupin has received approval for its Leflunomide Tablets USP, 10 mg and 20 mg, from the United States Food and Drug Administration (U .S. FDA), to market a generic equivalent of Arava Tablets, 10 mg and 20 mg, of SanofiAventis. The product would be manufactured at Lupin's Pithampur (Unit 1) facility, India.
Leflunomide Tablets USP, 10 mg and 20 mg, are indicated for the treatment of adults with active rheumatoid arthritis (RA) .
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
